Eli Lilly CDR (CAD Hedged)

AstraZeneca announced it will offer its diabetes drug Farxiga and asthma drug Airsupra at discounts of up to 70% through a new direct-to-consumer platform launching October 1, 2025.

Nigeria has signed a memorandum of understanding with China's Shanghai Haiqi Industrial Company Limited to establish what Chinese officials describe as Africa's first local insulin production facility.

Prellis Biologics announced a multi-target drug discovery collaboration with Eli Lilly combining Prellis' EXIS™ organoid platform with Lilly's development expertise.

Pfizer is acquiring Metsera, a nine-month-old biotech company, for $7.3 billion to gain access to innovative obesity therapeutics including a once-monthly GLP-1 agonist.

Myricx Bio has appointed Mohit Rawat as CEO, bringing extensive biopharma experience from Fusion Pharmaceuticals, which was acquired by AstraZeneca for $2.4 billion in 2024.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Novo Nordisk's once-weekly injectable diabetes treatment Kyinsu for adults with type 2 diabetes.

GeneDx appointed Lisa Gurry as Chief Business Officer to lead strategic partnerships and unlock the potential of GeneDx Infinity, the world's largest rare disease dataset with nearly one million exomes and genomes.

The FDA issued warning letters to Eli Lilly, Novo Nordisk, and Hims & Hers Health on September 9, 2025, for misleading advertising of weight-loss medications including Mounjaro, Zepbound, Ozempic, and Wegovy.

Dualitas Therapeutics launched from stealth with $65 million Series A funding co-led by Versant Ventures and Qiming Venture Partners USA, with participation from Eli Lilly and Company and other strategic investors.

Eli Lilly announces plans to build a $5 billion manufacturing facility in Virginia's Goochland County, marking the company's first dedicated bioconjugate platform and monoclonal antibody production site.